We've received numerous emails regarding where we are on our timeline in regards to our FDA IDE submission progress with RadioGel™ .
We have chosen to respond to the main inquiries in a question-and-answer format, which will allow us to disseminate the information to our entire shareholder base, and not one particular shareholder or potential investor. Please note that we will not respond individually to any email that requests confidential information that has not been properly vetted and disclosed to the public.
Retail investor questions and answers:
When is the next FDA meeting or has Vivos already had it?
What is the status of the genotoxicity proposal - is it ready?
Are you planning on submitting the IDE after the genotoxicity (proposal/testing/protocol) testing is finished, or are you staying on the same path?
Thank you for your continued support.
Mike Korenko, Sc. D
CEO & President Vivos Inc.
CONTACT:
Vivos Inc.
Michael K. Korenko, Sc.D.
President & CEO